ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2016
¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- The accuracy ofEuropean radiology · 2017Pooled it
- IntegratedEuropean journal of nuclear medicine and molecular imaging · 2018Trial
- Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.Molecular oncology · 2017Trial
- Article
- Diagnostic Performance ofNPJ breast cancer · 2026Article
- The Future of Quantitative Breast Imaging: Integrated to Integral Imaging Biomarkers for Precision Cancer Care, From theAJR. American journal of roentgenology · 2026Review
- [La Radiologia medica · 2026Review
- Per-patient Comparison of [Journal of Cancer · 2026Article
- Cryotherapy as a Surgical De-Escalation Strategy in Breast Cancer: Techniques, Complications, and Oncological Outcomes.Biomedicines · 2025Review
- Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.Clinical and translational science · 2025Article
- Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.Small science · 2025Review
- Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.Breast cancer research : BCR · 2025Article
- Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer UsingJCO clinical cancer informatics · 2025Article
- EDB-FN-targeted probes for near infrared fluorescent imaging and positron emission tomography imaging of breast cancer in mice.Scientific reports · 2024Article
- Monitoring of neoadjuvant chemotherapy through time domain diffuse optics: breast tissue composition changes and collagen discriminative potential.Biomedical optics express · 2024Article
- Changes in Intratumor Blood Flow After Carbon-Ion Radiation Therapy for Early-Stage Breast Cancer.International journal of particle therapy · 2024Article
- Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.Biomedicines · 2024Review
- Targeting the Warburg Effect in Cancer: Where Do We Stand?International journal of molecular sciences · 2024Review
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- PretreatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Changes in tumor metabolic activity have been shown to be an early indicator of treatment effectiveness for breast cancer, mainly in the neoadjuvant setting. The histopathologic response at the completion of chemotherapy has been used as the reference standard for assessment of the accuracy of (18)F-FDG PET in predicting a response during systemic treatment. Although a pathologic complete response (pCR) remains an important positive prognostic factor for an individual patient, a recent metaanalysis could validate pCR as a surrogate marker for patient outcomes only in aggressive breast cancer subtypes. For establishment of the clinical application of metabolic treatment response studies, larger series of specific breast cancer subtypes-including hormone receptor-positive, human epidermal growth factor receptor 2-positive, and triple-negative breast cancers-are necessary. In addition, thresholds for relative changes in (18)F-FDG uptake to distinguish between responding and nonresponding tumors need to be validated for different systemic treatment approaches, with progression-free survival and overall survival as references. A PET-based treatment stratification is applicable clinically only if valid alternative therapies are available. Of note, patients who do not achieve a pCR might still benefit from neoadjuvant therapy enabling breast-conserving surgery. In the metastatic setting, residual tumor metabolic activity after the initiation of systemic therapy is an indicator of active disease, whereas a complete resolution of metabolic activity is predictive of a successful treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.